Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Predictors of 30-day readmissions post-CAR-T in patients with relapsed/refractory multiple myeloma using the United States nationwide readmission database.
Journal: Annals of hematology
Published: January 11, 2026
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis.
Journal: Experimental hematology & oncology
Published: January 16, 2025
Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy.
Journal: Antioxidants (Basel, Switzerland)
Published: January 11, 2022
Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat.
Journal: Cancer drug resistance (Alhambra, Calif.)
Published: December 10, 2021
TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer.
Journal: Molecular cancer research : MCR
Published: July 30, 2019
Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
Journal: Cancer chemotherapy and pharmacology
Published: May 04, 2017
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.
Journal: Cancer cell
Published: December 19, 2012
Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting.
Journal: PloS one
Published: October 25, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026